Clinical trial · people

Setmelanotide: people with MC4R gene changes lost weight in 28 days

Checked against the paper Clinical trialPublished by PepVault

The takeaway

Setmelanotide produced weight loss in people with MC4R variants over 28 days, though less than in people with POMC defects, so how well it works may depend on which part of this pathway is affected.

Kind
Clinical trial
Studied in
People
Published
2017
Journal
Mol Metab

What they tested

The team wanted to know whether setmelanotide, a drug that switches on the MC4R receptor, can cause weight loss in people whose obesity comes with changes in the MC4R gene.

How the study was done

The work combined cell tests on mutant MC4R receptors, studies in normal mice and mice missing one or both copies of MC4R, a review of 369 published MC4R variants, and a 28-day phase 1b clinical trial in obese people carrying MC4R variants. Weight loss in that group was compared with people who have POMC defects and with obese controls.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking setmelanotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In the 28-day trial, people with obesity and MC4R variants lost weight on setmelanotide. People with POMC defects, which sit earlier in the same signaling path, lost significantly more weight than people with MC4R deficiency or obese controls. In mice, normal animals seemed more sensitive to the drug than mice missing one copy of MC4R, and mice missing both copies did not respond. In cells, setmelanotide was significantly more potent at MC4R than alpha-MSH, the body's own signal, and restored signaling to an outsized degree in some MC4R mutants with severe defects.

What it doesn’t show

This was a short, early-stage trial lasting 28 days, and the authors say more studies are needed to learn whether the weight loss is large enough to matter for health in some people with MC4R deficiency. The mouse and cell results are not human results.

The paper

Collet et al. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab. 2017.

The compound

More studies on Setmelanotide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking setmelanotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo